Recombinant Human VEGF 189 (aa 27-215) Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VEGF 189 (aa 27-215) Protein, CF Summary

• Details of Functionality: Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. The ED₅₀ for this effect is 4-40 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human VEGF protein
  Ala27-Arg215
• Accession #: AAA36804
• N-terminal Sequence: Ala27
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: VEGFA
• Purity: >95%, by SDS-PAGE with silver staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 22 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 22-30 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HCl.
• Purity: >95%, by SDS-PAGE with silver staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in 4 mM HCl.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGF 189 (aa 27-215) Protein, CF

• MVCD1
• VAS
• vascular endothelial growth factor A
• Vascular permeability factor
• Vasculotropin
• VEGF
• VEGFA
• VEGF-A
• VEGFMGC70609
• VPF
• VPFvascular endothelial growth factor

Background

VEGF₁₈₉ (Vascular Endothelial Growth Factor-A of 189 amino acids) is a 50-52 kDa homodimeric glycoprotein member of the PDGF/VEGF family of molecules (1, 2). A large number of human VEGF isoforms are generated by alternative splicing, including VEGF₁₈₉ which lacks amino acids (aa) 166-182 of the full length protein (VEGF₂₀₆) (3-5). Mature human VEGF₁₈₉ shares 88% aa sequence identity with mouse VEGF₁₈₈. VEGF₁₈₉ binds to heparan sulfate both on the cell surface and in the extracellular matrix (ECM) where it retains bioactivity (6, 7). It can undergo proteolytic cleavage from the ECM (at Arg136-Ala137), creating a soluble fragment with increased bioactivity (6, 7). VEGF₁₈₉ is widely expressed including by vascular smooth muscle cells (3), chondrocytes (8), fibroblasts (9), neuronal and glial cells (10), and neutrophils (11). VEGF₁₈₉ interacts with various receptors including VEGF R1, VEGF R2, Neuropilin-1, and Integrins aVb3, aVb5, a3b1, and a5b1 (6, 12-14). VEGF₁₈₉ exerts complex effects in angiogenesis. It is proapoptotic towards quiescent vascular endothelium but is proangiogenic towards endothelium that has committed to the angiogenic process (6, 14). In particular, venous endothelial cells are highly responsive towards VEGF₁₈₉, while the responsiveness of arterial endothelium is primarily restricted to the regulation of migration (7). In addition to its vascular effects,  immobilized VEGF₁₈₉ serves as an anchor for cells expressing Integrin avb3, and it acts as both a chemotactic and chemokinetic factor for migrating neutrophils (11, 13, 14).

1. Woolard, J. et al. (2009) Microcirculation 16:572.
2. Ferrara, N. et al. (2003) Nat. Med. 9:669.
3. Tischer, E. et al. (1991) J. Biol. Chem. 266:11947.
4. Leung, D.W. et al. (1989) Science 246:1306.
5. Keck, P.J. et al. (1989) Science 246:1309.
6. Plouet, J. et al. (1997) J. Biol. Chem. 272:13390.
7. Herve, M-A. et al. (2005) Exp. Cell Res. 309:24.
8. Cramer, T. et al. (2004) Osteoarthritis Cartilage 12:433.
9. Detmar, M. et al. (1997) J. Invest. Dermatol. 108:263.
10. Tang, H. et al. (2013) Neurobiol. Aging 34:1412.
11. Houck, K.A. et al. (1992) J. Biol. Chem. 267:26031.
12. Herve, M-A. et al. (2008) Am. J. Pathol. 172:167.
13. Hutchings, H. et al. (2003) FASEB J. 17:1520.
14. Vintonenko, N. et al. (2011) Cell Adh. Migr. 5:332.

Publications for VEGF (8147-VE/CF)(2)

Publications using 8147-VE/CF

• S Ma, LS Mangala, W Hu, E Bayaktar, A Yokoi, W Hu, S Pradeep, S Lee, PD Piehowski, A Villar-Pra, SY Wu, MH McGuire, OD Lara, C Rodriguez-, CJ LaFargue, NB Jennings, KD Rodland, T Liu, V Kundra, PT Ram, S Ramakrishn, G Lopez-Bere, RL Coleman, AK Sood CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance Cell Reports, 2021-08-17;36(7):109549. 2021-08-17 [PMID: 34407412] (Bioassay, Human)
• A Jahangiri, A Nguyen, A Chandra, MK Sidorov, G Yagnik, J Rick, SW Han, W Chen, PM Flanigan, D Schneidman, S Mascharak, M De Lay, B Imber, CC Park, K Matsumoto, K Lu, G Bergers, A Sali, WA Weiss, MK Aghi Cross-activating c-Met/?1 integrin complex drives metastasis and invasive resistance in cancer Proc. Natl. Acad. Sci. U.S.A., 2017-09-26;0(0):. 2017-09-26 [PMID: 28973887] (Bioassay, Human)

FAQs for VEGF (8147-VE/CF). (Showing 1 - 1 of 1 FAQs).

1. Why is the molecular weight of VEGF different from the similar antibody, for some companies the the molecular weight is 40KD)?
   • I can't comment on another company's antibody because I don't have any information about their products. I can tell you that VEGF is expressed in a variety of isoforms and is subject to various post-translational modifications that influence its apparent molecular weight in an SDS-PAGE gel compared to the theoretical molecular weight.

Bioinformatics

• Gene Symbol: VEGFA
• Uniprot:
  • AAA36804()